Posts Tagged: DAVID JENSEN
Evangelina, a former 'bubble baby,' plays inside a giant plastic bubble. (Photo: Stem Cellar Report, CIRM)
Little Evangelina Padilla-Vaccaro is more than a poster girl for the $12 billion California stem cell agency. She embodies a big bet by the agency that its efforts will conquer at least a few of the terrible diseases that are currently incurable. In the case of Evie, as the eight-year-old is known, she was born with what has come to be described as the bubble baby syndrome, a rare genetic mutation that crippled her immune system to the point that she would have died if left untreated.
A stem cell researcher at UC Davis. (Photo: AJ Cheline, UC Davis, via The Stem Cellar)
Backed by $17 million in cash from California’s stem cell agency, researchers at UC Davis this month are launching “the world’s first clinical trial using stem cells to treat spina bifida before the child is born.”
Stem cell researcher and professor Larry Goldstein. (Photo: Screen capture, UCTV).
Larry Goldstein, a well-known stem cell researcher at the University of California, San Diego who has received nearly $22 million in awards from the California stem cell agency, today was named to its governing board. It was the first time in the history of the 16-year-old agency that a scientist who has received agency awards has been appointed to the board.
Stem cell research using what's known as a PCR strip. (Image: Science Photo via Shutterstock)
California’s ambitious stem cell agency has launched itself on a new, $5.5 billion journey, approving a plan to hand out $182 million to researchers by the middle of next year and beefing up its efforts to bring equality to therapies and scientific labs.
A medical researcher examines cancer stem cells. (Photo: luchschenF, via Shutterstock)
Over the last 15 years, California’s stem cell agency has spent $2.7 billion on research on everything from cancer to arthritis. The vast majority of the money has gone to enterprises that have ties to members of the agency’s governing board. Eight out of every ten dollars that agency has handed out have been collected by 25 institutions such as Stanford University, multiple campuses of the University of California and scientific research organizations. Their combined total exceeds $2.1 billion.
Signature gathering during the 2018 election cycle. (Photo: Michael Gordon, via Shutterstock)
The $5.5 billion California stem cell initiative is virtually certain to qualify for the fall ballot as the arithmetic of the signature count begins to fall into place. The measure needs only slightly more than the 67 percent of the signatures that remain to be verified as coming from registered voters. The qualification percentage of raw signatures so far is 78 percent.
A photo illustration of the coronavirus pandemic and California. (Photo: bekulnis, via Shutterstock)
The state of California and its top medical regulator remain mired in a go-slow posture on the regulation of “snake oil” stem cell clinics that are currently riding the COVID-19 crisis to peddle dubious treatments to desperate patients. The marketing surge by the clinics has drawn increased attention nationally, including in prestigious scientific journals such as Cell Stem Cell whose usual fare deals with such things as “Stem Cell Hierarchy in Colorectal Cancer.”
A laboratory researcher examines cancer stem cells. (Image: science photo, via Shutterstock)
Backers of a $5.5 billion stem cell research proposal in California today have once again missed a self-imposed, but critical deadline as they continue to struggle with securing enough signatures to place the measure on the November ballot.
A lineup of mailboxes in rural California. (Photo: Elena Koulik, via Shutterstock)
The campaign to save California’s stem cell research program from financial extinction is making an “unprecedented,” electronic sprint to gather the final signatures to qualify its $5.5 billion rescue measure for the November ballot.
A clinical researcher with a multi-pipette arrangement of cancer stem cells. (Photo: Science Photo, via Shutterstock)
One of the nation’s leading regenerative medicine industry groups is touting multi-billion dollar savings that may be achieved with the type of stem cell and gene therapies that are being developed with cash from California’s financially beleaguered stem cell program.